ClinicalTrials.gg
CompletedNCT02035813Updated Jun 4, 2024

DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).

A Phase 2 interventional study of Ribociclib and Eribulin in HER2-negative and Hormone-receptor Positive Metastatic Breast Cancer, HER2-negative Circulating Tumor Cells and Postmenopausal Female Patients, sponsored by Prof. Wolfgang Janni. Completed at 1 site in Germany. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-04.

Sponsored by Prof. Wolfgang Janni · Phase 2, Interventional, and Treatment

How we know · 5 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
116
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 70 studies testing ribociclib in Breast Neoplasms — 17 open to participants now, 31 under way, 8 of them phase 3. ribociclib · Breast Neoplasms.

Enrollment
34th of 70
116 · median 116
Started
2014
with 4 others
Phase 2
27 of 70
8 open now
Registered
5th of 70
by date

Among the 70 studies testing ribociclib in Breast Neoplasms, this one is the 34th largest by enrollment, is one of 5 that started in 2014, is one of 27 in phase 2, and was the 5th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

17 of the 70 studies testing ribociclib in Breast Neoplasms are open now, in 11 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About ribociclib

ribociclib: first FDA approval 2017 (KISQALI), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing ribociclib in Breast Neoplasms, or all of them as a file.
02

Study summary

Several studies have indicated that determining prevalence and number of circulating tumor cells (CTCs) at various time points during treatment may be an effective tool for assessing treatment efficacy in metastatic breast cancer (MBC). However, even if the prognostic value of CTCs in MBC is well understood, the role of both CTC prevalence and CTC phenotype in predicting treatment response needs further investigation. DETECT IV is a prospective, multicenter, open-label, phase II study in patients with HER2-negative metastatic breast cancer and persisting HER2-negative circulating tumor cells (CTCs). Additional research on CTC dynamics and characteristics will provide a better understanding of the prognostic and predictive value of CTCs and is one step into a more personalized therapy for MBC.

03

Conditions studied

  • HER2-negative and Hormone-receptor Positive Metastatic Breast Cancer
  • HER2-negative Circulating Tumor Cells
  • Postmenopausal Female Patients

Keywords

  • metastatic breast cancer
  • circulating tumor cells
  • eribulin
  • ribociclib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Both cohorts:

  • Indication for an endocrine therapy (Histological confirmation of estrogen receptor positive (ER+) and/or progesterone receptor positive (PgR+) breast cancer).
  • Up to two lines of previous cytostatic treatment for MBC.
  • Any endocrine therapy in the history is allowed.
  • Disease progression following prior treatment with endocrine therapy (endocrine therapy does not have to be the last therapy before inclusion in the trial).
  • women. The investigator must confirm postmenopausal status Postmenopausal status is defined either by

    • Age ≥ 55 years and one year or more of amenorrhea
    • Age \< 55 years and one year or more of amenorrhea and postmenopausal levels of FSH and LH
    • Prior hysterectomy and has postmenopausal levels of FSH and LH
    • Surgical menopause with bilateral oophorectomy
  • Everolimus cohort:
  • Cholesterol ≤ 2.0 ×
  • Ribociclib cohort:
  • Standard 12-lead values assessed by the local laboratory:
    • interval at screening \< 450 msec (using Fridericia's correction)
    • Resting heart rate 50-90 bpm
  • ≤ 1,5 (ribocilclib cohort)
  • Patients must have the following laboratory values within normal limits or corrected to within normal lim-its with supplemets before the first dose of study medication:
  • -Sodium
  • -Potassium
  • -Total calcium

For Eribulin only:

  • Either hormone-receptor negative MBC or hormone-receptor positive MBC with indication for chemotherapy
  • Up to three previous chemotherapy treatment lines for disease
  • In case of patients of child bearing potential:

    • Negative pregnancy test (minimum sensitivity 25IU/L or equivalent units of HCG) within 7 days prior to recruitment
    • by means of a reliable method (i.e. non-hormonal contraception, IUD, a dou-ble barrier method, vasectomy of the sexual partner, complete sexual abstinence). Patient must consent in maintaining such contracep-tion until 3 months after completion of study treatment

Exclusion criteria

Exclusion Criteria:

In General for both study cohorts:

  1. Treatment with other agents of any type or anticancer therapy during the trial, within 2 weeks prior to the start of treatment.
  2. Adverse events due to prior anticancer therapy which are > Grade 1 () and therapeutically relevant at time of treatment start.
  3. Known infection.
  4. Current active or C, cliniclally relevant known liver dysfunction, e.g. according to Classifica-tion class B and C, or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gall-stones, liver or stable chronic non-viral liver disease per investigator assessment).
  5. Concurrent disease or condition that might interfere with adequate assessment or evaluation of study data, or any medical disorder that would make the patient's participation unreasonably hazardous.
  6. Other malignant diseases within the last 3 years (apart from carcinoma in situ of the cervix or non-melanoma skin cancer)
  7. Dementia, altered mental status, or any psychiatric or social condition which would prohibit the understanding or rendering of or which might interfere with the patient's adherence to the protocol.
  8. \< 3 months.
  9. Male gender.

For Everolimus/Ribociclib only:

  • Known to any of the of ribociclib, everolimus or any of the other given drugs.
  • Known hypersensitivity to lecithin (soya) and pea-nuts (ribocilib-cohort)
  • Disease or condition, which might restrain the ability to take or resorb oral medication. This includes malabsorption syndrome, requirement for intrave-nous (IV) alimentation, prior surgical procedures af-fecting absorption (for example resection of small bowel or stomach), uncontrolled inflammatory GI disease (e.g., Crohn's disease, ulcerative colitis) and any other diseases significantly affecting gas-trointestinal function as well as inability to swallow and retain oral medication for any other reason.

For Eribulin only:

  • History of hypersensitivity reactions attributed to eribulin.
  • Pre-existing neuropathy grade 3 or higher.
  • Severe Congenital long syndrome.
  • Pregnancy or nursing.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
116 participants (actual)

Study arms

  • Experimental
    Ribociclib in combination with standard endocrine therapy

    Postmenopausal female patients with hormone-receptor positive, HER2-negative metastatic breast cancer with HER2-negative circulating tumor cells (CTCs) and indication for standard endocrine therapy.

    Drug: Ribociclib

  • Experimental
    Eriubulin

    Patients with hormone-receptor positive, HER2-negative metastatic breast cancer and indication to chemother-apy or patients with triple-negative metastatic breast cancer, both with HER2-negative circulating tumor cells (CTCs).

    Drug: Eribulin

Interventions

  • Ribociclib/Everolimus in combination with endocrine therapy

    Also known as: Kisqali

  • Also known as: Halaven

06

What researchers measure

Primary outcomes

  1. Progression free survival (PFS)

    Time interval from randomization until progressive disease (PD) or death from any cause, whichever comes first

    Time frame: 8-12 weeks

Secondary outcomes

  1. Overall response rate

    Rate of complete (CR) and partial responses (PR) in patients with whom target lesions were defined

    Time frame: 8-12 weeks

  2. Disease control rate (DCR)

    rate of patients who were assessed as having a PR or a CR or who had stable disease (SD) for at least 6 months

    Time frame: 8-12 weeks

  3. Overall survival (OS)

    Time from randomization until death of any cause

    Time frame: 4 weeks

  4. Dynamic of CTCs

    Descriptive statistics of regular CTC counts

    Time frame: 8-12 weeks

  5. For Everolimus/Ribociclib cohort only: Levels of pS6

    Descriptive statistics of pS6 levels at baseline, at first radiological tumor assessment after about 12 weeks, and at the time of progression

    Time frame: 8-12 weeks

  6. For Everolimus/Ribociclib cohort only: Change in the activation of the PI3K/Akt/mTOR-pathway in CTCs

    Descriptive statistics of changes in the activation of the PI3K/Akt/mTOR-pathway in CTCs as assessed by longitudinal comparisons (at baseline, after 12 weeks, at time of progression)

    Time frame: 8-12 weeks

  7. For Everolimus/Ribociclib cohort only: Estrogen-receptor 1 (ESR-1) mutations in CTCs

    Estrogen-receptor 1 (ESR-1) mutations in CTCs at baseline, after 12 weeks and at time of progression

    Time frame: 8-12 weeks

  8. For Eribulin cohort only: New metastasis-free survival (nMFS)

    New metastasis-free survival (nMFS), defined as time from recruitment to death or progression due to appearance of a new metastasis, whichever comes first. If a patient has not had an event, nMFS is censored at the date of last adequate tumor as-sessment

    Time frame: 8-12 weeks

07

Study locations

1 site
  • University Hospital Ulm -Department of Gynecology
    Ulm, Baden-Württemberg 89075, Germany
08

References and documents

Related links

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2014 to primary completion in Jan 2024, 120 months.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's 120 months is above that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2014
First posted
Jan 14, 2014
StartActual
Jan 2014
Primary completionActual
Jan 10, 2024
CompletionActual
Jan 10, 2024
Last update
Jun 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02035813
Lead sponsor
Prof. Wolfgang Janni
Responsible party
Prof. Wolfgang Janni (University hospital Ulm - Department of Gynecology, University of Ulm) — Sponsor-investigator
First posted
Jan 14, 2014
Start date
Jan 2014
Primary completion
Jan 10, 2024
Completion
Jan 10, 2024
Last update
Jun 4, 2024

Study contacts

Tanja Fehm, MD, PhD
principal investigator · University Hospital Düsseldorf -Department of Gynecology
Wolfgang Janni, MD, PhD
study director · University Hospital Ulm -Department of Gynecology

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ribociclib · Eribulin

Start the discussion